Contact

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 14, 2024
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024 Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK Cash, cash equivalents, other financial assets

Read

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

Sep 03, 2024
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6-month open-label extension phase in Q1 2025 Phase 1 clinical trial to evaluate proprietary aerosol delivery device in

Read

GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer

Sep 03, 2024
DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the promotion of Dr. Velichka “Villy” Valcheva, MD, MSc.

Read

GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

May 03, 2024
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1 2025 Phase 2a clinical trial of GH001 in postpartum depression on track for expected completion in Q3

Read

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

Feb 29, 2024
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 Phase 2a clinical trial of GH001 in postpartum depression on track for expected completion in Q3 2024 Successfully completed Phase 1, dose-ranging

Read

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

Jan 18, 2024
DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it recently received a communication from the European Patent Office

Read